All posts by medical

‘Grey’s Anatomy’: Kelly McCreary Unsure If Meredith Grey Will Survive COVID: ‘We’re In Suspense’ – Yahoo Entertainment

Will Meredith Grey pull through? 'Grey's Anatomy' star Kelly McCreary told Access Hollywood that she really doesn't know how Meredith's battle with COVID-19 will play out on this season. Kelly shared that she doesnt want Ellen Pompeo's character to die, but she does love that Meredith was able to reunite with Patrick Dempsey's character Derek Shepard. Kelly also teased what fans can expect from her character Maggie Pierce.

View original post here:
'Grey's Anatomy': Kelly McCreary Unsure If Meredith Grey Will Survive COVID: 'We're In Suspense' - Yahoo Entertainment

Swamp Thing The Anatomy Lesson – CBS Pittsburgh

THE PRICE YOU PAY After being captured and taken to a Conclave facility, Swamp Thing (Derek Mears) is experimented upon by Jason Woodrue (guest star Kevin Durand), who makes an incredible discovery. Meanwhile, Abby (Crystal Reed) and Liz (Maria Sten) track down the secret facility to free Swamp Thing. Meanwhile, Daniel Cassidy (Ian Ziering) makes a fateful decision based on a possible future that the Phantom Stranger (guest star Macon Blair) shows him. The episode was directed by Michael Goi and written by Noah Griffith & Daniel Stewart with teleplay by Mark Verheiden (#109). The CW broadcast date airdate 12/15/2020 @ 8pm. Every episode of SWAMP THING will be available to stream on The CW App and CWTV.COM the day after broadcast for free and without a subscription, log in or authentication required.

See the rest here:
Swamp Thing The Anatomy Lesson - CBS Pittsburgh

‘Grey’s Anatomy’: Amelia Has Become a Fan-Favorite: ‘Every Minute With Her on Screen Is Just Magic’ – Showbiz Cheat Sheet

Super fans of Greys Anatomy have watched characters come and go over the shows 16 seasons, and when they go its usually wrenching and tragic.

There is one character that few would have mourned had she been run over by a bus or fallen out of the sky in a crashing plane Amelia Shepherd. But since this neurosurgeon Dr Shepherd sister of the much-missed Dr. McDreamy, Derek Shepherd appeared on the scene in Seattle in season 10, she has become a beloved character on the show.

Heres how a fan summed up Amelia on a recent Reddit thread.

I absolutely love her development. Shes whole, happy, radiant. An incredible mother and sister. Every minute with her on screen is just magic..

Canadian actress Caterina Scorsone, who plays Amelia, is a graduate of Trinity College, University of Toronto. As an undergrad she actually considered med school because she was such a fan of Greys Anatomy.

Instead, she continued acting and finally landed the role of Amelia on the Greys spin-off, Private Practice.

She was such a hit there that Shonda Rimes promoted her to Greys for the tenth season.

RELATED: Greys Anatomy Fans Demand the Return of Merediths Therapist

One thing you can count on with the docs at Seattle Grace/Grey Sloan is that there is romance in the supply closets and in Joes bar across the street. Amelias first fling was with Owen Hunt (Kevin McKidd) while he was on a break from Teddy (Greys version of Ross and Rachel) that ended in marriage.

Oh, and then she and Meredith (Ellen Pompeo) bonded and kept each other strong after the shocking and tragic and totally unnecessary death of Derek, but Amelia didnt have much storyline after the brain tumor and the divorce from Owen. She was not nice to the interns (seriously hampering romantic opportunities post-Owen) and didnt have a lot going on post-brain surgery, either.

The Betty/Britney storyline in season 14 explores addiction and really gives Amelia a strong storyline that doesnt have anything to do with romance. Betty is a former soccer star who got addicted to opioids after an injury. Leo is the son of an addict that Owen is fostering.

Because everybody who comes through Greys is related, Betty turns out to be Leos mom and Owen and Amelia take Betty in too. Amelia really came into her own as she helped Betty (whos real name is Britney) deal with her addiction, as it led Amelia to deal with her own issues and ultimately become a more sympathetic character.

Amelia and Link (Chris Carmack) met a couple of seasons back, and after they tried to ignore their attraction to each other, finally got together and had a baby at the end of Season 16.

Although Amelia wasnt entirely sure it was Links baby because Owen he promised to love it like his own anyway. So of course the paternity test proved it is Links.

Bailey was there to help Amelia with the birth of the baby, because Link had to operate on Dr. Webber (James Pickens). Aside from the concern that a giant research facility like Grey Sloan only has one orthopedist available for emergency surgery, the birth went off without a hitch and Amelia finally has her own healthy child.

This episode wasnt meant to be season finale, but Covid cut it short so the babys name wasnt revealed until season 17Scout Derek Shepherd.

Everybody is good so far, but in Shondaland that means something terrible is on the horizon. Stay tuned to Greys Anatomy to find out!

See the article here:
'Grey's Anatomy': Amelia Has Become a Fan-Favorite: 'Every Minute With Her on Screen Is Just Magic' - Showbiz Cheat Sheet

Who Is Patient Val Ashton With Premature Baby Luna on Greys Anatomy? – 2paragraphs Buzz

Mackenzie Marsh on Grey's Anatomy (ABC)

In the Greys Anatomy episode Fight the Power, while Bailey (Chandra Wilson) panics as she hears there has been a surge of COVID-19 cases, and Jackson (Jesse Williams) and Richard (James Pickens Jr.) team up against Catherine (Debbie Allen) to teach her a lesson, Carina (Stefania Spampinato) checks in with her patient Val Ashton (Mackenzie Marsh).

In the previous episode My Happy Ending a recently divorced Val came to the hospital with abdominal pain no knowing that she was pregnant. It turned out that a fetus was growing near her liver. After Carina performed an emergency C-section, Val named her 26-week-old daughter Luna who was intubated and then taken to the NICU.

Actress Mackenzie Marsh is known for her roles on Charmed (Knansie), Will & Grace (Vinces cousin and Drews ex-wife Angela), The Following (Tilda), and the 2016 movie Pee-wees Big Holiday (Judy Brown), among others.

Greys Anatomy airs Thursdays at 9 pm on ABC, right after Station 19 at 8 pm.

Read more here:
Who Is Patient Val Ashton With Premature Baby Luna on Greys Anatomy? - 2paragraphs Buzz

Is neuroscience the key to protecting AI from adversarial attacks? – TechTalks

This article is part of ourreviews of AI research papers, a series of posts that explore the latest findings in artificial intelligence.

Deep learning has come a long way since the days it could only recognize hand-written characters on checks and envelopes. Today, deep neural networks have become a key component of many computer vision applications, from photo and video editors to medical software and self-driving cars.

Roughly fashioned after the structure of the brain, neural networks have come closer to seeing the world as we humans do. But they still have a long way to go and make mistakes in situations that humans would never err.

These situations, generally known as adversarial examples, change the behavior of an AI model in befuddling ways. Adversarial machine learning is one of the greatest challenges of current artificial intelligence systems. They can lead machine learning models failing in unpredictable ways or becoming vulnerable to cyberattacks.

Creating AI systems that are resilient against adversarial attacks has become an active area of research and a hot topic of discussion at AI conferences. In computer vision, one interesting method to protect deep learning systems against adversarial attacks is to apply findings in neuroscience to close the gap between neural networks and the mammalian vision system.

Using this approach, researchers at MIT and MIT-IBM Watson AI Lab have found that directly mapping the features of the mammalian visual cortex onto deep neural networks creates AI systems that are more predictable in their behavior and more robust to adversarial perturbations. In a paper published on the bioRxiv preprint server, the researchers introduce VOneNet, an architecture that combines current deep learning techniques with neuroscience-inspired neural networks.

The work, done with help from scientists at the University of Munich, Ludwig Maximilian University, and the University of Augsburg, was accepted at the NeurIPS 2020, one of the prominent annual AI conferences, which will be held virtually this year.

The main architecture used in computer vision today is convolutional neural networks (CNN). When stacked on top of each other, multiple convolutional layers can be trained to learn and extract hierarchical features from images. Lower layers find general patterns such as corners and edges, and higher layers gradually become adept at finding more specific things such as objects and people.

In comparison to the traditional fully connected networks, ConvNets have proven to be both more robust and computationally efficient. There remain, however, fundamental differences between the way CNNs and the human visual system process information.

Deep neural networks (and convolutional neural networks in particular) have emerged as surprising good models of the visual cortexsurprisingly, they tend to fit experimental data collected from the brain even better than computational models that were tailor-made for explaining the neuroscience data, David Cox, IBM Director of MIT-IBM Watson AI Lab, told TechTalks. But not every deep neural network matches the brain data equally well, and there are some persistent gaps where the brain and the DNNs differ.

The most prominent of these gaps are adversarial examples, in which subtle perturbations such as a small patch or a layer of imperceptible noise can cause neural networks to misclassify their inputs. These changes go mostly unnoticed to the human eye.

It is certainly the case that the images that fool DNNs would never fool our own visual systems, Cox says. Its also the case that DNNs are surprisingly brittle against natural degradations (e.g., adding noise) to images, so robustness in general seems to be an open problem for DNNs. With this in mind, we felt this was a good place to look for differences between brains and DNNs that might be helpful.

Cox has been exploring the intersection of neuroscience and artificial intelligence since the early 2000s, when he was a student of James DiCarlo, neuroscience professor at MIT. The two have continued to work together since.

The brain is an incredibly powerful and effective information processing machine, and its tantalizing to ask if we can learn new tricks from it that can be used for practical purposes. At the same time, we can use what we know about artificial systems to provide guiding theories and hypotheses that can suggest experiments to help us understand the brain, Cox says.

For the new research, Cox and DiCarlo joined Joel Dapello and Tiago Marques, the lead authors of the paper, to see if neural networks became more robust to adversarial attacks when their activations were similar to brain activity. The AI researchers tested several popular CNN architectures trained on the ImageNet data set, including AlexNet, VGG, and different variations of ResNet. They also included some deep learning models that had undergone adversarial training, a process in which a neural network is trained on adversarial examples to avoid misclassifying them.

The scientist evaluated the AI models using the BrainScore metric, which compares activations in deep neural networks and neural responses in the brain. They then measured the robustness of each model by testing it against white-box adversarial attacks, where an attacker has full knowledge of the structure and parameters of the target neural networks.

To our surprise, the more brain-like a model was, the more robust the system was against adversarial attacks, Cox says. Inspired by this, we asked if it was possible to improve robustness (including adversarial robustness) by adding a more faithful simulation of the early visual cortexbased on neuroscience experimentsto the input stage of the network.

To further validate their findings, the researchers developed VOneNet, a hybrid deep learning architecture that combines standard CNNs with a layer of neuroscience-inspired neural networks.

The VOneNet replaces the first few layers of the CNN with the VOneBlock, a neural network architecture fashioned after the primary visual cortex of primates, also known as the V1 area. This means that image data is first processed by the VOneBlock before being passed on to the rest of the network.

The VOneBlock is itself composed of a Gabor filter bank (GFB), simple and complex cell nonlinearities, and neuronal stochasticity. The GFB is similar to the convolutional layers found in other neural networks. But while classic neural networks with random parameter values and tune them during training, the values of the GFB parameters are determined and fixed based on what we know about activations in the primary visual cortex.

The weights of the GFB and other architectural choices of the VOneBlock are engineered according to biology. This means that all the choices we made for the VOneBlock were constrained by neurophysiology. In other words, we designed the VOneBlock to mimic as much as possible the primate primary visual cortex (area V1). We considered available data collected over the last four decades from several studies to determine the VOneBlock parameters, says Tiago Marques, PhD, PhRMA Foundation Postdoctoral Fellow at MIT and co-author of the paper.

While there are significant differences in the visual cortex of different primate, there are also many shared features, especially in the V1 area. Fortunately, across primates differences seem to be minor and in fact there are plenty of studies showing that monkeys object recognition capabilities resemble those of humans. In our model with used published available data characterizing responses of monkeys V1 neurons. While our model is still only an approximation of primate V1 (it does not include all known data and even that data is somewhat limited there is a lot that we still do not know about V1 processing), it is a good approximation, Marques says.

Beyond the GFB layer, the simple and complex cells in the VOneBlock give the neural network flexibility to detect features under different conditions. Ultimately, the goal of object recognition is to identify the existence of objects independently of their exact shape, size, location and other low-level features, Marques says. In the VOneBlock it seems that both simple and complex cells serve complementary roles in supporting performance under different image perturbations. Simple cells were particularly important for dealing with common corruptions while complex cells with white box adversarial attacks.

One of the strengths of the VOneBlock is its compatibility with current CNN architectures. The VOneBlock was designed to have a plug-and-play functionality, Marques says. That means that it directly replaces the input layer of a standard CNN structure. A transition layer that follows the core of the VOneBlock ensures that its output can be made compatible with rest of the CNN architecture.

The researchers plugged the VOneBlock into several CNN architectures that perform well on the ImageNet data set. Interestingly, the addition of this simple block resulted in considerable improvement in robustness to white-box adversarial attacks and outperformed training-based defense methods.

Simulating the image processing of primate primary visual cortex at the front of standard CNN architectures significantly improves their robustness to image perturbations, even bringing them to outperform state-of-the-art defense methods, the researchers write in their paper.

The model of V1 that we added here is actually quite simplewere only altering the first stage of the system, while leaving the rest of the network untouched, and the biological fidelity of this V1 model is still quite simple, Cox says, adding that there is a lot more detail and nuance one could add to such a model to make it better match what is known about the brain.

Simplicity is strength in some ways, since it isolates a smaller set of principles that might be important, but it would be interesting to explore whether other dimensions of biological fidelity might be important, he says.

The paper challenges a trend that has become all too common in AI research in the past years. Instead of applying the latest findings about brain mechanisms in their research, many AI scientists focus on driving advances in the field by taking advantage the availability of vast compute resources and large data sets to train larger and larger neural networks. And as weve discussed in these pages before, that approach presents many challenges to AI research.

VOneNet proves that biological intelligence still has a lot of untapped potential and can address some of the fundamental problems AI research is facing. The models presented here, drawn directly from primate neurobiology, indeed require less training to achieve more human-like behavior. This is one turn of a new virtuous circle, wherein neuroscience and artificial intelligence each feed into and reinforce the understanding and ability of the other, the authors write.

In the future, the researchers will further explore the properties of VOneNet and the further integration of discoveries in neuroscience and artificial intelligence. One limitation of our current work is that while we have shown that adding a V1 block leads to improvements, we dont have a great handle onwhyit does, Cox says.

Developing the theory to help understand this why question will enable the AI researchers to ultimately home in on what really matters and to build more effective systems. They also plan to explore the integration of neuroscience-inspired architectures beyond the initial layers of artificial neural networks.

Says Cox, Weve only just scratched the surface in terms of incorporating these elements of biological realism into DNNs, and theres a lot more we can still do. Were excited to see where this journey takes us.

Here is the original post:
Is neuroscience the key to protecting AI from adversarial attacks? - TechTalks

Innovative Companies Diving into The Neuro Market Ahead of 2021 – BioSpace

With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Modernas COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?

It will if the following five companies, which all launched this year with Series A financing, have anything to say about it.

Vigil Neuroscience

Led by industry veteran Ivana Magovevi-Liebisch, Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia.

A type of neuroglia located throughout the brain and spinal cord, microglia are the first line of immune defense for the central nervous system (CNS). As they are responsible for detecting plaques, damaged or unnecessary neurons, synapses, and infections, their inefficiency can lead to neuroinflammatory, neuropsychiatric, and neurodegenerative diseases, including Epilepsy, Parkinsons disease Multiple Sclerosis, and many types of dementia.

Vigils pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction.

Vigils $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., which will remain a key shareholder.

SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals was also born this week, launched by Lilly Asia Ventures Fund and Arch Venture Partners, co-leaders of its $100 million Series A financing.

The financing advances the establishment of a robust and innovative CNS pipeline, focusing initially on the Greater China region.

One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patients to their families and society as well, said SciNeuro Founder and chief executive officer, Min Li, Ph.D., in a statement.

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. His company, which also includes Qiuqing Ang, M.D., Ph.D. as chief medical officer, and Danny Chen, Ph.D. as SVP & Head of Translational Science, will be particularly focused on CNS diseases where there is a major unmet need.

Genesis Therapeutics

Spun out of CEO and co-founder Evan Feinbergs breakthrough artificial Intelligence (AI) research at Stanford Universitys Pande Lab, Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs.

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets, Feinberg said at the time of the launch.

Genesis went public on December 2 in a round of $52 million Series A financing led by Rock Springs Capital. Dr. Kris Jenner of Rock Springs, who joins Genesis board of directors, is a renowned healthcare investor who has invested in several successful biotech companies.

Libra Therapeutics

California-based Libra Therapeutics launched in September with $29 million in Series A financing, co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital and Sant.

Libra, which means balance when translated to English, hopes to restore balance to the brains neurons. The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy.

Its like taking out the trash. It clears out the toxic proteins that build up in the neuron, thereby allowing the neuron to function properly, said Libra President and CEO Isaac Veinbergs, formerly of Acadia Pharmaceuticals and Sanofi.

Libra will use this approach, along with the $29 million infusion, to develop novel small molecule drug candidates for the treatment of neurodegenerative diseases.

Tranquis Therapeutics

An immuno-neurology company with a focus on neurodegenerative and aging-related diseases,Tranquis Therapeutics beat the aforementioned four to the show, launching on July 9 with $30 million in Series A funding, led by Remiges Ventures and SR One.

Tranquis platform is based on the groundbreaking work of its scientific founder, Professor Edgar Engleman, M.D., and his team at Stanford University, which posits that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

The company is developing small molecule therapeutic candidates that cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction associated with many CNS diseases.

While its original work focused on orphan diseases such as Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, the team, led by President and CEO Sanjay Kakkar, M.D., will branch out to join the fight against more widespread illnesses, Parkinsons and Alzheimers.

For our lead program, TQS-168, we have demonstrated in vitro the ability to restore a key metabolic pathway we have shown is dysfunctional in the myeloid immune cells of patients with neurodegenerative diseases, as well as highly encouraging in vivo effects in challenging neurodegenerative disease models, Kakkar said at the time of the launch.

Most read today on BioSpace:

More here:
Innovative Companies Diving into The Neuro Market Ahead of 2021 - BioSpace

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors – GlobeNewswire

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board of Directors. Dr. McKernan currently serves as a venture partner with SV Health Investors, LLP, a global investment firm and specialist healthcare fund manager, where she supports companies that create new medicines for treating neurodegenerative disorders. With over 25 years of academic, research and commercial experience in the pharmaceutical industry, Dr. McKernan also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK, the countrys leading dementia research charity.

Dr. McKernan is an outstanding scientific leader with deep expertise in the biopharmaceutical industry and she will bring a wealth of knowledge and experience in neuroscience disorders to our board, said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. Dr. McKernans guidance will help us as we seek to innovate the treatment landscape and bring new therapies to individuals facing some of the most vexing diseases including schizophrenia, epilepsy and Parkinsons disease.

I am honored to join the board of Cerevel, a neuroscience company that is working hard to bring new treatments to patients, said Dr. McKernan. Cerevel aspires to be the premier neuroscience company, and I look forward to contributing to the realization of that goal.

About Dr. Ruth McKernanDr. McKernans distinguished career has spanned the academic, business and government worlds. She has over 25 years of research and commercial experience in the pharmaceutical industry, including leading research units in the United Kingdom and the United States. Currently, Dr. McKernan is a venture partner with SV Health Investors, LLP, a global investment firm focused on the healthcare industry. At SV, Dr. McKernan focuses on companies that create new medicines for treating neurodegenerative disorders, including AstronauTx, a UKbased biotechnology company for which she serves as chairperson. She also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK.

Previously, Dr. McKernan served in a variety of senior leadership roles while at Pfizer, including as vice president, chief scientific officer of Regenerative Medicine, and chief scientific officer of Neusentis. In those roles, she initiated multiple neuroscience partnerships, acquisitions and spinouts and played an active part in taking more than 10 compounds into the clinic. Prior to Pfizer, Dr. McKernan served in multiple senior positions at Merck over the course of an 18-year tenure at the company. As a neuroscientist, Dr. McKernan has over 120 publications and 15 patents in the areas of ion channels and regenerative medicine. Her first book for nonscientists, Billys Halo, was shortlisted for the Mind Book of the Year Award (2007), a literary award which celebrates writing that contributes to public understanding of mental health issues. Dr. McKernan earned her bachelors degree in pharmacology with biochemistry from Kings College London and received a Ph.D. in biochemical pharmacology from the University of London.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and substance use disorders. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our potential to become a premier neuroscience company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

Read more:
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors - GlobeNewswire

Timeline of key events in McMaster’s investigation in its Department of Psychology, Neuroscience and Behaviour – TheSpec.com

Investigation into McMaster's psychology department and sexual violence on campus

For nearly a year, McMaster has been investigating serious allegations of sexual assault and sexual harassment involving individuals in its Department of Psychology, Neuroscience and Behaviour (PNB).

On Thursday, the university released a report on the findings of a review into the department. The report found there are systemic and cultural issues within the PNB, including numerous reports of sexual harassment, and a degree of complacency that has let inappropriate behaviours go unchecked.

But while the report into the culture of the department is now complete, investigations into the more serious allegations of sexual harassment and sexual violence remain ongoing.

Below is a timeline of the events in 2020 that unfolded leading up to this weeks report.

Feb. 19: Maureen J. MacDonald, dean of science, sends an email to the PNB department and students affected by the situation stating a professor in the department has been suspended and barred from campus following serious allegations that possibly involve a number of university policies, including the sexual violence policy.

March 19: The Spectator obtains a copy of MacDonalds letter and confirms police are investigating Scott Watter, a professor in McMasters PNB department. Watters lawyer confirms his client has been placed on nondisciplinary leave of absence without loss of pay pending the outcome of an investigation into alleged breaches of university policies.

June 18: Police put out a release saying Watter, 46, is facing charges of sexual assault and sexual assault causing bodily harm for incidents that occurred in 2017 involving a female student. Police say they believe there may be other victims.

July 27: McMaster retains Rubin Thomlinson LLP, a law firm specializing in workplace investigations, to conduct a systemic review of the Department of Psychology, Neuroscience and Behaviour.

July 28: McMaster announces its original investigation under the universitys sexual violence and discrimination and harassment policies is being broadened to identify any potential systemic or cultural issues within the department that need to be surfaced and addressed. The broadened investigation is the climate review.

The university also announces it has suspended two more department faculty members. The faculty members are also banned from campus. They are not named, nor is anyone else sanctioned by the university in coming months. The university also does not provide details regarding the allegations levelled against the faculty members, nor does it provide details of allegations against those sanctioned.

Aug. 6: McMaster says a graduate student has been suspended and is no longer allowed on campus. The decision came after new allegations came to light relating to the universitys sexual violence and discrimination and harassment policies.

Aug. 21: McMaster says it has restricted another faculty member from interacting with students after new allegations were made under the universitys discrimination and harassment policy.

Sept. 30: McMaster says a former staff member in the PNB department who now works in another area of the university is on a leave of absence after a complaint about an alleged past sexual assault. The person is also banned from campus. Additionally, a second person who is a current department staff member was barred from interacting with students due to a separate allegation. The university said it was investigating both incidents under the universitys sexual violence policy.

Dec. 3: The university announces the review is complete and releases a report on its findings. The review uncovered systemic and cultural issues, including allegations of sexual harassment and a lack of boundaries between students and faculty, and a degree of complacency that has let inappropriate behaviours go unchecked, the report states.

Loading...Loading...Loading...Loading...Loading...

On Dec. 24: Watter is next scheduled to appear in court.

Moving forward: The university says that it will implement such measures as additional trauma-informed training for department staff and faculty. For students, it will offer training on sexual harassment, including providing information on accessing support. Equity, diversity and inclusion expertise will be provided to the department. The university will also commit to helping the department build on its research and teaching strengths.

Here is the original post:
Timeline of key events in McMaster's investigation in its Department of Psychology, Neuroscience and Behaviour - TheSpec.com

Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -…

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aural Analytics, Inc., the industry leader in speech neuroscience and speech analytics technologies, announced today the initiation of a multi-product pivotal study to demonstrate the safety and efficacy of its speech-based tools for measuring pulmonary function and speech motor function in amyotrophic lateral sclerosis (ALS). The company anticipates submitting the results of this multi-site, multi-language, 280 participant, prospective, blinded study to the U.S. Food and Drug Administration (FDA) in late 2021. The study, conducted as part of the Target ALS Diagnosis Initiative, is one of several pivotal studies Aural Analytics is set to kick off in 2021 as it expands its suite of clinical-grade speech-based digital tools.

The Aural Analytics VCP software tool enables on-demand, real-time objective evaluation of pulmonary function by predicting forced vital capacity (FVC) and forced expiratory volume (FEV1) without the need for specialized hardware in-clinic and at-home. These measurements are commonly used in the assessment of airflow obstruction (COPD, asthma) and restrictive lung disease (ALS). The VCP software is currently being used as one approach to screen for eligibility in the Healey Center ALS platform trial at Massachusetts General Hospital. Aural Analytics will also use the study to further demonstrate the safety and efficacy of its speech-based assessment software that enables on-demand, real-time objective monitoring of symptoms and progression in diseases known to impact bulbar function (speech and swallowing).

Aural Analytics is enabling clinical-grade speech analytics in areas of critical unmet patient and clinical need. This study will be the basis of multiple regulatory submissions for products that have broad clinical utility and commercial pathways, said Daniel Jones, co-founder and CEO of Aural Analytics. We continue to work closely with regulators at the FDA and key stakeholders across the healthcare industry to ensure safe, reliable, repeatable and transparent speech-based tools are brought to market.

More about the Aural Analytics VCP Software in ALS

Respiratory failure is the leading cause of death in patients with ALS. As a result, regular assessment of respiratory function is the standard of care. People with ALS often have problems achieving valid measures on standard in-clinic or at-home spirometers. Lip weakness can prevent creation of a tight seal around the spirometer and some with ALS experience an involuntary slamming shut of their vocal cords when they exhale forcefully. Spirometers often induce bouts of coughing which, given the COVID-19 pandemic, has made it increasingly difficult to objectively measure respiratory function in-clinic. Our VCP software is designed to tap into both inspiratory and expiratory muscle strength, without requiring lip strength, and with far less chance of inducing laryngospasm or coughing, said Dr. Julie Liss, co-founder and chief clinical officer at Aural Analytics. Our application enables a patient to easily deliver pulmonary function data, remotely, with just a few short tasks. The outcome measures are clinically relevant, interpretable, reliable and highly repeatable.

More about the Aural Analytics Speech Motor Control Software

Functional rating scales have been used historically to capture the impact of disease on a person's daily life. These rating scales are often coarse, subjective, and can miss key information about how a patient is doing. We have found that the information we extract from speech samples tracks well with a number of functional rating scales for different diseases, said Dr. Liss. Yet, more importantly, our speech metrics can detect changes in disease before they have functional consequences and in a far more frequent, objective way. We believe this tool will provide an opportunity for greater precision in clinical management.

The Aural Analytics VCP and speech motor assessment applications further add to the companys technology suite which includes mobile applications currently available for use in clinical research and clinical settings, an embeddable mobile and web SDK, web-progressive applications, and APIs, all with cloud-based computation that power disease-specific speech tasks and analytics.

About Aural Analytics, Inc.

Aural Analytics is the industrys leading speech neuroscience company building the worlds most advanced clinical-grade speech analytics platform for health applications across the lifespan. Its suite of mobile-first, patient-centric applications, available in up to 30 languages across Android, iOS and the web are easy to use, secure, and provide robust, clinically relevant, interpretable and validated metrics reflecting the neurological and respiratory health of its users. The company is founded on nearly three decades of NIH and NSF-funded research in speech neuroscience, is backed by dozens of high-caliber scientific publications, and has won several awards for its work in the field, including the prestigious Global SCRIP Award for Best Technology Development in Clinical Trials. Aural Analytics is based in Scottsdale, AZ. For more information, please visit auralanalytics.com or follow Aural Analytics on Twitter, LinkedIn, Medium and Facebook.

About Target ALS

Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigs disease. We envision a world in which no one dies of ALS and play a unique role in the battle against this disease. Founded in 2013 by former New York City deputy mayor Dan Doctoroff who lost both his father and uncle to ALS our approach is breaking down barriers and silos that previously inhibited research results. We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry. The Target ALS Innovation Ecosystem has revolutionized the field in just seven years through collaborations that have resulted in the first potential treatments since ALS was identified in 1869.

To date, the Target ALS Innovation Ecosystem, which launched in 2013 and set the groundwork for the new Target ALS Diagnosis Initiative, has yielded 175+ research projects, 12+ therapeutic targets and five clinical trials, to date.

About The Target ALS Diagnosis Initiative

Target ALS launched the first-ever comprehensive effort to discover ALS biomarkers The Target ALS Diagnosis Initiative through which the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources. The initiative was developed in response to input from over 100 scientists, patients, caregivers and other thought leaders. They universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.

The Target ALS Diagnosis Initiative strategically focuses on three promising areas:

See the article here:
Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -...

Global Neuroscience Antibodies and Assays Market Analysis by 2020-2025 – Industry Today

The global Neuroscience Antibodies and Assaysmarket size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Read the original here:
Global Neuroscience Antibodies and Assays Market Analysis by 2020-2025 - Industry Today